The results show that all per‐protocol participants developed a clear positive neutralisation response to SARS‐CoV‐2, with a parallel rise in anti‐S1‐IgG and anti‐S1‐IgA antibodies, confirming previously published data on antibody kinetics after COVID‐19 vaccination.1, 2. This evidence concerns the gene CD79A and COVID-19.